Abstract:Abstract The aim of this retrospective study was to assess the ‘miss rate’ of dermatology clinicians for detecting malignant melanoma among patients referred on the 2-week-wait skin cancer pathway over a 2-year period. We reviewed patient records from the previous 5 years to identify instances where malignant melanoma might have been misdiagnosed. Malignant melanoma can be missed at various stages of the patient’s journey, leading to delayed diagnosis and potentially serious consequences. Our geographically isolated rural county relies exclusively on a single NHS dermatology department for 2-week-wait skin cancer services, providing a unique opportunity to assess the incidence of missed melanoma. We used a regional cancer registry to identify all primary invasive malignant melanomas (ICD-10 C43) diagnosed between August 2020 and July 2022. Records of any patient who had attended the dermatology department within the 5 years preceding diagnosis were reviewed to identify patients where melanoma might have been previously misdiagnosed. In total, 432 primary melanomas were identified. The male-to-female ratio was 202 : 230 and the median age was 71 years (interquartile range 57–79). Stage at presentation was IA (176, 40.7%), IB (98, 22.7%), II (134, 31.0%), III (19, 4.4%) and IV (5, 1.2%). Nine patients (2.1%) had been given an erroneous benign diagnosis for the same lesion and discharged within 13 months of diagnosis (missed melanoma). The stages of the missed melanomas were IA (two patients), IB (four patients) and II (three patients). In a further four cases (0.9%) the melanoma had prompted action, but the diagnosis was delayed; one had an erroneous negative biopsy, one missed an urgent review, one lesion was monitored, leading to a 6-month delay in diagnosis, and one was incorrectly diagnosed as a basal cell carcinoma, leading to a delay in surgery. A final four (0.9%) cases were diagnosed as benign more than 2 years prior to melanoma diagnosis. These were classified as ‘possible’ misses, as they could have evolved into malignant melanomas in the interim period. Our study reveals a low yet quantifiable melanoma miss rate in a high-volume NHS dermatology service. Future multicentre studies with large datasets are required, to identify risk factors for misdiagnosis. Clinicians managing skin lesion clinics may consider melanoma miss rate as a key performance metric. Strategies to improve the accuracy of this important metric might include the use of prospective databases incorporating digital images of lesions suspected to be benign. The utility of this approach should be investigated further.

Diagnostic discordance among histopathological reviewers of melanocytic lesions

A Clinicopathological Analysis of Melanocytic Nevi: A Retrospective Series

Comparison between melanoma gene expression score and fluorescence in situ hybridization for the classification of melanocytic lesions

DP20 A case series identifying the clinical and histopathological characteristics of amelanotic melanoma

Distribution Quantification on Dermoscopy Images for Computer-Assisted Diagnosis of Cutaneous Melanomas

Pathology of melanocytic lesions: New, controversial, and clinically important issues

Appropriate Statistical Methods to Assess Cross-study Diagnostic 23-Gene Expression Profile Test Performance for Cutaneous Melanocytic Neoplasms

Understanding diagnostic variability in breast pathology: lessons learned from an expert consensus review panel

Dermoscopy and reflectance confocal microscopy of solitary flat pink lesions: A new combined score to diagnose amelanotic melanoma

Advances in Technology for Melanoma Diagnosis and Prognosis: An Expert Consensus Panel

P023 Real-world melanoma miss rate in an NHS hospital dermatology service

Clinical Impact and Accuracy of Shave Biopsy for Initial Diagnosis of Cutaneous Melanoma

Teledermoscopic triage of melanoma-suspicious skin lesions is safe: A retrospective comparative diagnostic accuracy study with multiple assessors

Preoperative bimodal imaging evaluation in finding histological correlations of in situ, superficial spreading and nodular melanoma

Dermoscopic, Histological, Confocal Microscopy Correlation of Atypical-Dysplastic Melanocytic Nevi

Establishing Consensus for Mohs Micrographic Surgical Techniques in the Treatment of Melanoma in Situ for Future Clinical Trials: A Modified Delphi Study

Contemporary management of patients with advanced melanoma: Utility of an online interactive decision support tool to assess concordance of healthcare professional treatment patterns with expert recommendations.

Misdiagnosis and Clinical Insights into Acral Amelanotic Melanoma—A Systematic Review

Misdiagnosis Analysis of 2291 Cases of Haematolymphoid Neoplasms

Patterns of Major Frozen Section Interpretation Error: An In-Depth Analysis From a Complex Academic Surgical Pathology Practice

How dermatologic surgeons decide to proceed with surgery for nonmelanoma skin cancer when site identification is initially uncertain: A nationwide, multicenter, prospective study